Introduction
Hydroxyethyl starch (HES) preparations are artificial colloid solutions used for intravascular volume expansion and provision of plasma oncotic support during periods of hypoproteinaemia. Plasma volume expansion is achieved by the high plasma colloid oncotic pressure (pCOP) generated through retention of large osmotically active molecules within the vasculature following i.v. administration [1] .
Hydroxyethyl starches are produced by hydrolysis and subsequent hydroxyethylation substitution of amylopectin, a branched polysaccharide polymer [2] . Since the introduction of 1st generation HES (hetastarch), 2nd (pentastarch) and 3rd generation (tetrastarch) HES have been developed with different mean molecular weight (MW), degree of molar substitution (MS), C 2 /C 6 ratio and concentration [3] . These parameters determine the pharmacokinetics of the product and potential side effects, including coagulopathies, may be more frequent following the administration of first and second generation HES solutions. Tetrastarch (130/0.4) is a novel 3rd generation HES with an average MW of 130 kDa, which is smaller than that of hetastarch, and a MS of 0.4 to enhance degradation and limit potential side effects [4] . Preparations can be derived from either maize or potato starch. 4 Colloids are restricted to the intravascular space resulting in more rapid intravascular volume replacement and expansion compared to crystalloids which distribute among the extracellular fluid spaces [5, 6] . Fluid resuscitation with crystalloids in horses with hypoproteinaemia may therefore lead to further dilution of plasma proteins and a decrease in oncotic pressure, contributing to oedema formation [7, 8] . Intravenous administration of colloids has been found to maintain pCOP and plasma volume even when there is increased capillary permeability and albumin leakage [9] . Colloid solutions can therefore be used to restore and maintain pCOP in horses affected by these conditions [8] .
Despite potential advantages associated with HES administration, the use of artificial colloids is limited by concerns of reported adverse effects including allergic reactions, coagulopathies, substantially higher costs, and recent reports of an increased risk of renal failure and mortality in critically ill human patients compared with crystalloid administration [4, 10, 11] . Specific coagulation side effects include decreased circulating factor VIII and von Willebrand factor concentrations, impairment of platelet function and decreased fibrin clot stabilisation [4] and have been described in dogs and horses [1, 12] . Other potential complications associated with i.v. colloid administration include haemodilution effects causing decreases in total serum protein and albumin [1, 12, 13] .
Many reports describe the potential benefits of colloid administration in horses [1, 8, 14] , however, information regarding their oncotic and potential adverse effects is limited. The in vitro effects of HES solutions on coagulation and platelet function in horses have recently been described [15] , and potential changes in coagulation following HES administration have been investigated in vivo [1, 16] . Reported adverse effects are predominantly dose-related [1, 15] , and current recommendations for maximum daily tetrastarch dosage requirements in horses are mostly extrapolated from human literature. This study was designed to estimate the coagulation and oncotic pressure effects of tetrastarch (130/0.4) administration in healthy horses. We hypothesised that lower dosages would not be associated with adverse effects on coagulation, and that all dosages administered would increase pCOP.
Material and methods

Study design
Six clinically healthy, non-pregnant Nooitgedacht pony mares with a mean age of 5.3 years (range 2-10 years), and mean body mass 422 kg (380-440 kg), from the Onderstepoort Teaching Animal Unit were selected for the study. Mares were considered clinically healthy on the basis of normal physical examination findings, normal complete blood count and serum biochemistry, and normal haemostatic assays as determined by thromboelastography (TEG). All mares were hospitalised on Day 1 and 2 of each administration protocol and received ad libitum grass (Eragrostis tef) and alfalfa (Medicago sativa) hay and had free access to water. Thereafter they were housed in sheltered outside paddocks and were fed ad libitum hay with free access to water until study completion.
Treatment administration
Treatments were randomly allocated to each mare using a prospective cross-over was administered intravenously to each mare once every 2 weeks at three dosages: 10, 20, and 40 ml/kg bwt. Treatments were administered as an intravenous bolus by gravity using 500 ml tetrastarch bags. To maintain a constant flow rate, all bags were maintained at a pre-set height and connected to a high flow (10 drops/ml) administration set c prior to colloid administration.
Blood sampling and analyses
Venipuncture of the right jugular vein was performed for the measurement of pCOP, 
Data analysis
Data were described using means, standard deviations, and calculating the change from baseline to 12 h post-infusion. Data were assessed for normality by evaluating descriptive statistics, plotting histograms and performing the Anderson-Darling normality test within statistical software i . Data that were not normally distributed (Rtime, K-time and pCOP) were transformed using either the natural logarithm or by ranking prior to statistical analysis and described as median and interquartile range (IQR). A general linear modelling approach that incorporated adjustment for the repeated sampling of horses was used to analyse coagulation and blood parameter data. Linear mixed models were fit including fixed effect terms for tetrastarch dose, time of sampling, week of the study, and an interaction between dose and sampling time. A random effect for horse was included and a first order autoregressive correlation structure was used to adjust for repeated measurements. Post hoc comparisons were adjusted using the Bonferroni correction of P values. Statistical modelling was performed in commercially available software j and results interpreted at the 5% level of significance (P<0.05).
Results
No adverse behavioural changes related to treatment were observed. Mean ± s.d. administration times for the 10, 20 and 40 ml/kg bwt dosages were 20.5 ± 1.64 min, 44.6 ± 10.57 min and 77.1 ± 7.96 min respectively.
Thromboelastometric values at baseline were comparable with the established inhouse laboratory reference ranges for kaolin-activated TEG (Table 1) . Overall R-time values differed significantly by tetrastarch dose (P<0.001), and the median (IQR) R- (Table 1) . In contrast, α-angle did not change significantly over time in any of the 3 treatment groups, but there was an overall significant difference by tetrastarch dose (P<0.001).
The mean (s.d.) α-angle change from baseline to 12 h was -3.05 (3.89), -1.90 (7.28), and -11.08 (13.99) for the 10, 20 and 40 ml/kg bwt groups respectively. There were significant differences between the 10 and 40 ml/kg bwt (P<0.001), and the 20 and 40 ml/kg bwt (P=0.031) treatment groups.
Overall MA values differed significantly by tetrastarch dose (P<0.001) and the mean (Table 3) .
Administration of 20 and 40 ml/kg bwt tetrastarch induced significant decreases in TS and PCV with significant differences persisting up to 6 h after infusion for the 20 ml/kg bwt and up to 12 h for the 40 ml/kg bwt dose. Significant changes were not observed for platelet count in the 10 ml/kg bwt treatment group, but significant changes were detected up to 6 h after infusion of 20 ml/kg bwt and up to 1 h following infusion of 40 ml/kg bwt tetrastarch (Table 3) .
Discussion
In the present study 3 treatment protocols were evaluated to determine the effect of tetrastarch (130/0.4) on coagulation in healthy pony mares. All TEG variables measured remained within established reference ranges. However, the administration of higher doses of tetrastarch (40 ml/kg bwt especially) were more likely to induce changes in coagulation as evidenced by a prolonged K-time and decreased MA. The changes in TEG variables over time is consistent with reports describing haemostatic alterations after HES administration in other species [1, 12, 13] . Hypocoagulation as measured by TEG has also been described in humans receiving HES [17] .
The clot strength, represented by MA, is dependent on platelet function, concentration and platelet-fibrin interaction [18] . The observed decrease in MA in the present study could be partially explained by the concurrent observed decrease in platelet concentration. Despite these reported alterations in haemostatic variables, studies in humans confirm that tetrastarches have minimal effect on coagulation compared to Thromboelastography was chosen to assess coagulation because it provides information concerning the entire haemostatic system and thus a global assessment of coagulation. Thromboelastography has been evaluated for use in horses but high variability in measured parameters of healthy horses has also been recognised [20, 21] .
Only 2 operators performed TEG in the present study to limit variability. A limitation involving haemostatic analyses in the present study is that conventional laboratory tests of haemostasis (e.g. PT, aPTT and fibrinogen) were not performed, and haemostatic results can therefore not be directly compared to similar studies evaluating the effect of HES on these haemostatic variables. The study was also performed in healthy horses and the effect of HES solutions on coagulation during sepsis and inflammation may differ.
Administration of tetrastarch to healthy mares caused a significant increase in pCOP in all 3 treatment groups persisting to 24 h in the 10 ml/kg and to 48 h in the 40 ml/kg bwt groups. In the present study, osmotic effectiveness was only significant to 6 h after tetrastarch infusion at 20 ml/kg bwt. Although significance was only observed for up to 6 h, mean pCOP values remained above baseline throughout the 96 h observation period. Mean pCOP values at baseline were comparable with previously reported values for horses [8, 22] . The magnitude of the observed increases in pCOP were similar to the changes reported in clinically normal ponies, in which the administration of hetastarch at 10 and 20 ml/kg bwt caused a dose-dependent increase in pCOP for up to 120 h [1] . Osmotic effectiveness depends on the number of oncotically active particles retained within the vasculature and their rate of elimination. Following HES administration, smaller molecules below the renal threshold are rapidly excreted, whereas larger molecules are retained within the vasculature and subsequently hydrolysed into progressively smaller fragments by α-amylase until reaching the renal threshold for excretion [3] . This process causes an increasing number of HES molecules, thereby enhancing the oncotic effect. Thus, a lower MW product will provide more molecules in a given volume of HES solution compared to a high MW product, therefore exerting a greater pCOP at a similar concentration. The rate of elimination of HES particles is influenced by speciesspecific differences in plasma α-amylase activity [23, 24] . Elimination of tetrastarch in horses has not been reported, however, the prolonged effects on pCOP observed in this study suggest that there is prolonged intravascular retention of oncotically active particles after infusion. Jones et al. [1] reported sustained osmotic effectiveness after hetastarch administration throughout a 120 h observation period. Also, a significant oncotic effect lasting 24 h was reported after administration of hetastarch in hospitalised horses [8] . Pharmacokinetic differences in HES products based on MW and MS could explain the differences in duration of osmotic effectiveness in this study compared to others.
Haemodilution is an indirect method of assessing plasma volume expansion and previous studies have shown that erythrocyte mass and total circulating protein are not affected after HES infusion [25] . lower MW and MS [3] . Studies have shown that clearance of tetrastarch is at least 23 times faster than that of hexastarch or hetastarch [3, 26] . In humans undergoing orthopaedic surgery, enhanced clearance of tetrastarch was confirmed by 1 mg/ml plasma concentrations of tetrastarch compared to 2.6 mg/ml for pentastarch by the end of the first postoperative day [27] . The lower MW and MS of tetrastarch (130/0.4) compared to hetastarch (6% HES 450/0.7) used in the study by Jones et al. [1] may explain the observed difference in haemodilution.
An adequate platelet count is essential for normal haemostasis and platelet concentrations < 100 x 10 9 /l can increase cutaneous bleeding time [28] . Hydroxyethyl starch solutions are thought to bind directly to the glycoprotein IIb-IIIa receptor on the platelet surface, preventing outside to inside signalling on the platelet membrane, platelet up-regulation and eventually preventing the formation of a platelet plug and clot [4] . The degree of MS is thought to play a more substantial role in platelet inhibition [29] . A reduction in platelet count has been reported in dogs, humans and horses and is attributed to haemodilution due to plasma volume expansion [1, 4, 12] .
Platelet count was not significantly decreased in the 10 ml/kg bwt treatment group in the present study. Although significant reductions in platelet count were observed in the 20 and 40 ml/kg bwt treatment groups, these did not decrease platelet concentrations below 100 x 10 9 /l and the duration was not as prolonged as reported by
Jones et al. [1] . The reduction in platelet count in this study was proportional to the observed decrease in PCV and TS, suggesting that the decrease was associated with haemodilution.
Hydroxyethyl starch administration may influence total solids as measured by refractometer in the present study. To obtain a more accurate representation of plasma protein concentration, an automated serum biochemical analyser is preferable. There is, however some evidence that the refractive index correlates well with plasma protein concentration [30] .
Earlier reports raised concerns about the possible deleterious effects of HES on renal function and recent meta-analyses have confirmed these concerns in critically ill humans [10, 11] . When HES 130/0.4, the preparation used in this study, and saline were evaluated as a resuscitation fluid for humans in intensive care, no significant difference in 90-day mortality was detected between patients, however more patients required renal replacement therapy following resuscitation with HES [31] . In contrast, resuscitation with a different formulation HES 130/0.42 (Tetraspan 6%), resulted in both an increased mortality and need for renal replacement therapy compared to resuscitation with Ringer's acetate [32] . Meta-analyses of randomised, controlled trials of critically ill adult patients involving any formulation of HES concluded that compared with other resuscitation solutions the use of HES was associated with a significant increased risk of mortality and acute kidney injury. In humans, a high fraction of HES is taken up and deposited in tissues, and renal deposition has been Potato-derived HES 130/0.42 is the only tetrastarch reported to be contraindicated in humans with severe hepatic impairment due to induced hyperbilirubinaemia [34] . In the present study bile acid concentration was measured up to 96 h post-infusion and results were not consistent with impaired liver function. Routine bile acid and creatinine measurements were still normal in 4 out of the 6 mares examined 8 months after completion of the study (the other 2 mares were not examined).
Other limitations of this study were that the pharmacokinetics of tetrastarch (130/0.4) in horses is unknown and a washout period of 2 weeks was chosen in the absence of specific data concerning the half-life. The rate of elimination of HES particles is influenced by species-specific differences in plasma α-amylase activity [23, 24] and amylase activity in equine plasma seems to be lower than amylase activity in humans [24] . In the present study treatments were randomised and adjustments were included in the statistical analyses in effort to control for any carry-over effect. A further limitation was that data were not recorded between the 1 and 6 h time points and thus the effects of tetrastarch during this period are unknown. Selected time points for blood sampling were chosen based on the expected duration of effect of tetrastarch on the variables investigated as well as from previous studies investigating the effect of HES [1] . The limited duration of osmotic effectiveness following infusion of 20 ml/kg bwt tetrastarch could be explained by the limited number of horses used in the study.
In conclusion, this study indicates that tetrastarch (130/0.4) administered at 10 and 20 ml/kg bwt has minimal effects on haemostatic variables as measured by TEG.
Although still within normal reference ranges, compared to lower dosages, infusion of 40 ml/kg bwt tetrastarch is more likely to induce dose-related changes in indicators of coagulation, as evidenced by an increased coagulation time and decreased overall clot strength. Administration thereof effectively increased pCOP, and exerted dosedependent haemodilutional effects in healthy horses. The beneficial effects of HES in horses are more likely to be associated with provision of oncotic support during periods of hypoproteinaemia rather than resuscitation as described in humans.
Therefore, tetrastarch (130/0.4) has potential as a synthetic colloid in horses.
Extrapolation of data between species should be done with caution, however, in light of recent concerns in humans, further investigation of administration in critically ill horses is needed to evaluate potential side effects as described in humans.
